FDA Approval Gives BeOne Medicines a New Challenger to AbbVie, Roche Cancer Drug

BeOne Medicines drug Beqalzi has accelerated FDA approval for treating relapsed or refractory mantle cell lymphoma, a sort of blood most cancers. The regulatory nod opens the door to probably compete towards Venclexta, a blockbuster most cancers drug marketed by AbbVie and Roche.

The submit FDA Approval Provides BeOne Medicines a New Challenger to AbbVie, Roche Most cancers Drug appeared first on MedCity Information.

Source link